Ovarian and Cervical Cancers Update

November 2005
PharmaWatch: Cancer;Nov2005, Vol. 4 Issue 11, p6
Market Research Report
The article presents information about various studies related to ovarian and cervical cancers. A phase II study of Avastin in advanced ovarian cancer has been suspended by Genentech Inc. after an increased rate of gastrointestinal bleeding was found in the patients. Cervical cancer vaccine produced by Merck and Co. Inc. in collaboration with Sanofi-Aventis SA, has been proved to be 100% effective in preventing early stage cervical cancer, in a stage III clinical trial. In order to validate and characterize ovarian cancer biomarkers as well as to discover potential new biomarkers, Ciphergen Biosystems Inc. will work with the University College London and UCL BioMedica PLC.


Related Articles

  • Sanofi-Aventis: Avastin boosts Eloxatin chemo.  // PharmaWatch: Cancer;Mar2005, Vol. 4 Issue 3, p9 

    The article discusses the results of using Avastin with Eloxatin-based chemotherapy regimens for metastatic colorectal cancer. Sanofi-Aventis SA declared that the clinical trials made on combining the two drugs had showed positive results and provided greater hope of survival to patients. The...

  • Ciphergen Biosystems Introduces ProteinChip Biomarker System.  // Drug Discovery & Development;Nov2002, Vol. 5 Issue 10, p19 

    Reports that Ciphergen Biosystems Inc. has announced the release of its ProteinChip AutoBiomarker System at the 52nd Annual Meeting of the American Society of Human Genetics held in Baltimore, Maryland, from October 15-19, 2002. Features of the system; Company clientele.

  • Ciphergen Presents Protein Biomarker Discoveries.  // Drug Discovery & Development;Jul/Aug2002, Vol. 5 Issue 7, p25 

    Reports on the presentation of studies involving the SELDI ProteinChip technology of Ciphergen Biosystems Inc. at the American Society for Mass Spectrometry Conference in Orlando, Florida. Use of the technology in proteomics research; Discovery of multiple protein biomarkers and biomarker...

  • Selling Reputation.  // Pharmaceutical Executive;Jul2006, Vol. 26 Issue 7, p30 

    The article focuses on the survey which states that the physicians' interactions with drug sales representatives influenced their views of pharmaceutical companies. In a survey of 320 oncologists, it was found out that Genentech enjoyed the most positive image, followed by Amgen, Novartis, and...

  • Merck and Lundbeck: Sanofi set to benefit from drug failure.  // PharmaWatch: CNS;May2007, Vol. 6 Issue 5, p9 

    The article reports on the impact of the negative result of the phase III data for gaboxadol manufactured by Merck & Co. Inc. and Lundbeck on the market leader Sanofi-Aventis. Sanofi's drug Ambien will not face considerable competition from a Merck marketed alternative. The market for...

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p10 

    The article offers news briefs related to the pharmaceutical industry. Merck & Co. Inc. has completed the acquisition of NovaCardia Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular disease. Meanwhile, Sanofi Aventis SA has announced that one-year findings...

  • Oncology. Pines, Noah // Medical Marketing & Media;Oct2011, Vol. 46 Issue 10, p38 

    The article offers information on pharmaceutical company's focus on targeted therapies for the treatment of cancer. Analyst Tim Anderson of Sanford Bernstein says that molecular understanding and targeted therapeutics is unique to oncology. It also include a table that lists the top 50 oncology...

  • Cancer News Round-up.  // PharmaWatch: Cancer;Nov2005, Vol. 4 Issue 11, p2 

    The article presents news related to the oncology industry. Sanofi-Aventis SA has been in the limelight due to announcements made by it related to three different cancer drugs. Food and Drug Administration orphan drug designation has been granted to ZymoGenetics Inc. for Interleukin 21 (IL-21)...

  • Oncology. Noah Pines // Medical Marketing & Media;Sep2012, Vol. 47 Issue 9, p46 

    The article discusses the oncology medicine launches from the newly approved drugs for cancer. It notes that marketing executive Alexander Hardy at Roche/Genentech reveals that every medicine in development has a corresponding biomarker program. It explores the top chemotherapy and targeted...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics